Casma Therapeutics said it will develop CSM-101 as a potential disease-modifying oral treatment for people with Parkinson’s disease and Gaucher disease. CSM-101 is a first-in-class small molecule designed to activate the calcium channel TRPML1, a key regulator of lysosomal function and autophagy, a process in which cells deliver…
People with Parkinson’s disease who have mild cognitive changes before deep brain stimulation (DBS) are not more likely to develop dementia later in life than those whose cognitive function was normal before the surgery, a Danish study has found. Instead, the researchers observed that dementia was more likely…
Rune Labs and the Parkinson’s Foundation are partnering on a clinical program to identify genetic and digital biomarkers showing how genetics and daily symptoms are connected in people with Parkinson’s disease, with the aim of speeding diagnosis, improving clinical trial design, and supporting the development of more targeted treatments. The…
Cure Parkinson’s is funding SLEIPNIR, a multiarm clinical trial platform that will simultaneously test up to three disease-modifying treatments for Parkinson’s disease — assessing whether any of them can engage with their intended targets in the brain. The results are expected to help decide if these treatments should…
The first patient has been dosed in a pivotal Phase 2/3 clinical trial testing BHV-8000, a brain-penetrant oral small molecule that Biohaven Therapeutics is developing as a disease-modifying therapy for neuroinflammatory conditions, including Parkinson’s disease. The clinical trial (NCT06976268) is evaluating the effectiveness and safety of BHV-8000…
Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain. That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently…
Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a favorable pharmacological profile in the second part of a Phase 1 trial. This part of the Phase 1 clinical trial (NCT06493045) tested the safety and tolerability of multiple ascending…
Barriers including physical difficulties and social stigma may affect how people with Parkinson’s disease use assistive devices meant to help facilitate movement and prevent falls, a study found. Parkinson’s patients said physicians prescribing assistive devices helped them overcome stigma or negative associations. Other possible interventions, including education initiatives and…
A gene therapy tool dubbed AAV-DB-3, being developed by Latus Bio to deliver therapeutic genetic material into cells, is able to reach deep structures in the brain — among them ones that become damaged in neurodegenerative disorders such as Parkinson’s disease — a study in mice, monkeys, and lab-grown…
REM sleep behavior disorder (RBD) can mean restless nights for people with Parkinson’s disease and their partners, and add to symptoms, such as cognitive impairment and problems with blood pressure or digestion, that make daily life more difficult for both, a study shows. To ease any tension, couples often…
Get regular updates to your inbox.
